Portfolio breakdown

POSITIONS
Amgen
8.50%
Argenx SE
7.90%
Vertex Pharmaceuticals
7.80%
Gilead Sciences
7.40%
Revolution Medicines
5.50%
Oruka Therapeutics
4.40%
Insmed
4.10%
Scholar Rock
3.80%
Nuvalent
3.70%
Viridian Therapeutics
3.50%
Relay Therapeutics
3.30%
Vaxcyte
3.20%
Crinetics Pharmaceuticals
2.80%
Regeneron Pharmaceuticals
2.80%
United Therapeutics Corporation
2.80%
BridgeBio Pharma
2.50%
Immunocore
2.50%
Enliven Therapeutics
2.10%
Ionis Pharmaceuticals
2.10%
Vera Therapeutics
2.00%
Jade Biosciences
1.90%
Ultragenyx Pharmaceutical
1.90%
Rivus Pharmaceuticals
1.50%
Celldex Therapeutics
1.30%
Avalyn Pharma
1.20%
Disc Medicine
1.20%
Damora Therapeutics
1.20%
CG Oncology
1.00%
Krystal Biotech
0.80%
Monte Rosa Therapeutics
0.80%
Annexon
0.70%
Palvella Therapeutics
0.70%
Seaport Therapeutics
0.70%
Hemab Therapeutics
0.60%
Spyre Therapeutics
0.60%
Tango Therapeutics
0.60%
Parabilis Medicines
0.40%
Aura Biosciences
0.20%
Niroda Therapeutics
0.10%
Disease area
Orphan Diseases
Inflammation & Immunology
Oncology
Infectious Diseases
Cardiovascular Diseases
Neurological Diseses
market capitalization (in usd)
> 30 bn
5 - 30 bn
1 - 5 bn
500 mn - 1 bn
Private
Technology
Small Molecule
Biologics
RNA
Gene- and cell therapy

Facts & key figures

Investment Focus

Innovative biotechnology companies developing differentiated therapies

Primarily invested in listed biotechnology companies, with selective private investments

20-50 target participations

5–8 core positions with meaningful portfolio weights

suitability & risk profile
Designed for long-term investors (5+ years) willing to accept equity risk typical of the biotech sector.
Lower Risk
Higher Risk
Risk metrics (3Y)
1.1
Beta (3Y)
26.2%
Volatility (3Y)
13.3%
Tracking Error
0.73
Sharpe Ratio
NBI (Nasday Biotechnology Index) is used as the benchmark and the reference currency is CHF.
general information
Investment manager
Bellevue Asset Management AG
Custodian bank
Bank Julius Bär AG
Launch date
09.11.1993
Fiscal year end
December 31
Management fee
1.10% p.a.
Legal form
Incorporate company
SFDR category
Article 8

Benefits & risks

Access to global biotech growth

Diversified portfolio of profitable and pipeline companies

Experienced investment management

Dividend policy (~5%)

Equity volatility

Biotech sector swings

Currency risks

Discount/premium to NAV

Up to 15% leverage possible